Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Allory

Showing results (151-160 of 208) with videos related to

Pageof 21
Sort By:
European Urology Oncology|July 8, 2026
Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-makingConstance Thibault, Hélène Blons, Yves Allory, et al.
The French Journal of Urology|April 17, 2026
Guidelines from the cancer (CCAFU) and infection disease (CI-AFU) committees of the French association of Urology for the management of adverse events and complications of BCGPriscilla Leon, Laura I Levi, Thibaut Long Depaquit, et al.
European Urology|October 5, 2015
Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary CarcinomasJulien Calderaro, Julien Masliah-Planchon, Wilfrid Richer, et al.
Annals of Surgical Oncology|May 10, 2026
Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer CommitteePierre-Etienne Gabriel, Thomas Seisen, Evanguelos Xylinas, et al.
The Journal of Pathology|March 17, 2012
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinomaSandra Rebouissou, Aurélie Hérault, Eric Letouzé, et al.
International Journal of Surgical Pathology|April 25, 2022
The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory AnalysisLaura S Mertens, Francesco Claps, Roman Mayr, et al.
European Urology Oncology|April 16, 2025
Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST ProjectAlexandra Masson-Lecomte, Guillaume Grisay, Julien Van Damme, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2023
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24)Constance Thibault, Aude Fléchon, Laurence Albiges, et al.
Cancers|November 11, 2022
Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer CommitteeAlexandra Masson-Lecomte, Victoire Vaillant, Mathieu Roumiguié, et al.
Cell Reports|December 3, 2014
Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypesAnne Biton, Isabelle Bernard-Pierrot, Yinjun Lou, et al.
Pageof 21

Showing results (151-160 of 208) with videos related to

Sort By:
Pageof 21
European Urology Oncology|July 8, 2026
Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-makingConstance Thibault, Hélène Blons, Yves Allory, et al.
The French Journal of Urology|April 17, 2026
Guidelines from the cancer (CCAFU) and infection disease (CI-AFU) committees of the French association of Urology for the management of adverse events and complications of BCGPriscilla Leon, Laura I Levi, Thibaut Long Depaquit, et al.
European Urology|October 5, 2015
Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary CarcinomasJulien Calderaro, Julien Masliah-Planchon, Wilfrid Richer, et al.
Annals of Surgical Oncology|May 10, 2026
Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer CommitteePierre-Etienne Gabriel, Thomas Seisen, Evanguelos Xylinas, et al.
The Journal of Pathology|March 17, 2012
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinomaSandra Rebouissou, Aurélie Hérault, Eric Letouzé, et al.
International Journal of Surgical Pathology|April 25, 2022
The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory AnalysisLaura S Mertens, Francesco Claps, Roman Mayr, et al.
European Urology Oncology|April 16, 2025
Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST ProjectAlexandra Masson-Lecomte, Guillaume Grisay, Julien Van Damme, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2023
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24)Constance Thibault, Aude Fléchon, Laurence Albiges, et al.
Cancers|November 11, 2022
Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer CommitteeAlexandra Masson-Lecomte, Victoire Vaillant, Mathieu Roumiguié, et al.
Cell Reports|December 3, 2014
Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypesAnne Biton, Isabelle Bernard-Pierrot, Yinjun Lou, et al.
Pageof 21